Benzinga · Feb 24, 2026
HC Wainwright & Co. Maintains Buy on Balchem, Maintains $190 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Balchem (NASDAQ:BCPC) with a Buy and maintains $190 price target.
NASDAQ · BCPC
Balchem Corporation
Basic Materials · Chemicals - Specialty
$166.67
Down-$1.67 (-0.99%)
Updated Sep 11, 2026, 10:54 AM
SID Score
4.8/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 5.09B
- P/E ratio
- 34.44
- Dividend yield
- 0.52%
- 52-week range
- $139.17 – $183.90
- Volume
- 127.77K
- Avg. volume
- 172.4K
Price performance
BCPC price history
1M range · 0 trading sessions · Daily adjusted prices
BCPC does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest BCPC news
The latest Smart Investors Daily articles mentioning BCPC.
Stock researchCompany · Overview
BCPC research
Overview
Company profile and research snapshot.
Company profile
Balchem Corp is engaged in the development, manufacture, and marketing of specialty performance ingredients and products for various industries. The company's reportable segments are; Human Nutrition and Health, which generates maximum revenue, and provides human-grade choline nutrients and mineral amino acid chelated products through this segment for nutrition and health applications; Animal Nutrition and Health, which provides nutritional products derived from its microencapsulation and chelation technologies in addition to the essential nutrient choline chloride; and the Specialty Products segment includes re-packaging and distributing several performance gases and chemicals. Geographically, the company derives its key revenue from the United States and the rest from foreign countries.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $175.50
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 3, 2026 | HC Wainwright & Co. | Buy | — |
| May 4, 2026 | HC Wainwright & Co. | Buy | — |
| Feb 24, 2026 | HC Wainwright & Co. | Buy | — |
| Dec 5, 2025 | Rothschild & Co | Neutral | — |
| Oct 22, 2025 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Feb 20, 2026
Balchem Corporation (BCPC) Q4 2025 Earnings Call Transcript
ChartMill · Feb 20, 2026
Balchem Corp. (NASDAQ:BCPC) Reports In-Line Q4 2025 Earnings and Record Annual Revenue
Balchem Corp. (BCPC) reports record 2025 results, surpassing $1B in revenue. Q4 earnings met analyst expectations with steady growth across all segments.
SeekingAlpha · Feb 20, 2026
Balchem Corporation 2025 Q4 - Results - Earnings Call Presentation
2026-02-20. The following slide deck was published by Balchem Corporation in conjunction with their 2025 Q4 earnings call.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
